Attached files
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 26, 2015
CANNAPHARMARX, INC.
---------------------
(Exact name of Registrant as specified in its charter)
Delaware 000-27055 24-4635140
------------------------------- -------------------------- -------------------
(State or other jurisdiction of (Commission File Number) (IRS Employer Ident
incorporation) -ification No.)
One Collins Drive, Suite 100, Carneys Point, NJ 08069
--------------------------------------------------
(Address of principal executive offices)
(856) 376-0500
-----------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
SECTION 5 - CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Effective February 27, 2015, the Company appointed Wendy DiCicco and David Pohl
to its Board of Directors. Biographies of each new director are as follows:
Wendy DiCicco, age 47, Director
Ms. DiCicco is currently an independent consultant serving a number of clients
in the orthopedic and pharmaceutical industries. Ms. DiCicco most recently
served as the Chief Financial Officer of Nuron Biotech, Inc., a privately-held
biotech company, developing specialty biologics and marketing vaccines
internationally for the prevention and treatment of infectious and
neurodegenerative disease. Prior to Nuron, for sixteen years, Ms. DiCicco served
as Chief Financial Officer for both private and public companies with a focus in
the orthopedic and cardiovascular medical device industries, including Globus
Medical and Kensey Nash Corporation. Ms. DiCicco also serves on the board of
directors of II-VI, Incorporated, a public company, where she was elected in
2006 and serves on the Audit (chair), Compensation and Governance and Nominating
Committees. Ms. DiCicco started her career at Deloitte & Touche, LLP, where she
was an Accounting and Audit Manager before beginning her career as an industry
executive. Ms. DiCicco holds a B.S in Accounting from Philadelphia College of
Textiles and Science and is a Certified Public Accountant in the Commonwealth of
Pennsylvania. Ms. DiCicco is a National Association of Corporate Directors
(NACD) Governance Fellow. Ms. DiCicco adds financial reporting and management
skills to our board as a result of her career, including her experience with a
large public accounting firm and as the CFO of both public and private
companies.
David Pohl, age 55, Director
David Pohl brings over 30 years of leadership experience in healthcare-related
businesses to the CannaPharmaRx Board. Currently, he is an Executive Vice
President with TridentUSA Health Services, a national provider of bedside
diagnostic and laboratory services. Prior to this position, he was the Chief
Operating Officer of MobilexUSA, the largest operating company within TridentUSA
Health Services. David held a number of senior management positions at Cardinal
Health, including his role as the Senior Vice President of Retail National
Accounts where he was part of the pharmaceutical distribution business. Prior to
joining Cardinal, he was with Dentsply International where he held the position
of National Sales Manager in the U.S. before moving to the role of Managing
Director of Dentsply's Australian operations, based in Melbourne, Australia. He
also held management positions with Hill-Rom/Support Systems International and
American Hospital Supply Corporation and is currently a member of the Advisory
Board of ProactiCare LLC. David holds a B.A. from Bucknell University with a
double major in Biology and Geology.
2
SECTION 7 - REGULATION FD
Item 7.01 Regulation FD Disclosure
The information in this Item 7.01 of this Current Report is furnished pursuant
to Item 7.01 and shall not be deemed "filed" for any purpose, including for the
purposes of Section 18 of the Exchange Act, or otherwise subject to the
liabilities of that Section. The information in this Current Report on Form 8-K
shall not be deemed incorporated by reference into any filing under the
Securities Act or the Exchange Act regardless of any general incorporation
language in such filing.
On February 26, 2015, the Company announced the appointment of two new members
to its Board of Directors, effective February 27, 2015.
SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits
The following is a complete list of exhibits filed as part of this
Report. Exhibit numbers correspond to the numbers in the exhibit table of Item
601 of Regulation S-K.
Exhibit # Description
99.1 Press Release dated February 26, 2015
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CANNAPHARMARX, INC.
By: /s/ Gerry Crocker
---------------------------------------
Name: Gerry Crocker
Title: Chief Executive Officer
Date: March 2, 2015
